A Decile Is a Rear‑View Mirror

Decile is the most trusted number in pharma targeting, and for good reason. It’s simple, it’s comparable, and for established physicians past volume is a fair guide to future volume.

Advanced practice is where that stops holding.

Two blind spots

The first is time. Decile is built on trailing prescribing history. A newly licensed NP or PA has none, so she sits at the bottom of the file or off it entirely, often at the very moment she’s forming the habits she’ll prescribe from for years. By the time her volume earns a decile, those habits are set.

The second is attribution. When a writer’s scripts are credited elsewhere (see №02), her decile understates her twice: once for being new, and again for being invisible.

Same decile, different opportunity

Even among established prescribers, decile hides the question a brand actually needs answered. Two clinicians can sit in the same decile with very different futures. One has already given the brand most of what she can. The other has room to grow and the patients to do it. Decile ranks them the same, so the budget treats them the same.

The better questions look forward: how much headroom does this prescriber have for our brand, and what is our probability of capturing it? Read NPI by NPI, those two measures turn a ranked list into decisions: invest, resolve what’s blocking, maintain or deprioritize.

Keep decile. Stop steering by it.

Decile still belongs in the plan as a description of the past. It just can’t be the steering wheel for the fastest-growing part of the prescriber base.